NCT01057732

Brief Summary

Primary hyperparathyroidism (PHPT) is associated with increased cardiovascular morbidity. The benefit of surgical treatment in this respect is unclear. This study was performed to evaluate the impact of parathyroidectomy (PTX) on cardiovascular risk profile.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
76

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2005

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2005

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2006

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2006

Completed
3.2 years until next milestone

First Submitted

Initial submission to the registry

January 25, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 27, 2010

Completed
Last Updated

January 27, 2010

Status Verified

January 1, 2010

Enrollment Period

1.4 years

First QC Date

January 25, 2010

Last Update Submit

January 25, 2010

Conditions

Primary Hyperparathyroidism

Study Arms (2)

primary hyperparathyroidism

patients with primary hyperparathyroidism

controls

subjects without primary hyperparathyroidism

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with Primary hyperparathyroidism referred to Endocrine clinic. Controls recruited in community-based health centers.

You may qualify if:

  • Patients with primary hyperparthyroidism

You may not qualify if:

  • Individuals with known diabetes mellitus,coronary heart disease, stroke

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Endocrine Institute, Haemek Medical Center

Afula, 18101, Israel

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum, urine

MeSH Terms

Conditions

Hyperparathyroidism, Primary

Condition Hierarchy (Ancestors)

HyperparathyroidismParathyroid DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 25, 2010

First Posted

January 27, 2010

Study Start

January 1, 2005

Primary Completion

June 1, 2006

Study Completion

December 1, 2006

Last Updated

January 27, 2010

Record last verified: 2010-01

Locations

IL(1)